For example, IL-1β has long been implicated in the pathogenesis of both type 2 diabetes and atherosclerosis, and Canakinumab (anti-IL-1β-neutralising monoclonal antibody) is currently the focus of extensive clinical investigation for these indications17. This evidence concerns the gene IL1B and type 2 diabetes mellitus.